BridgeBio Cash vs Net Debt Analysis

BBIO Stock

USD 34.77 0.86 2.54%

BridgeBio Pharma financial indicator trend analysis is way more than just evaluating BridgeBio Pharma prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether BridgeBio Pharma is a good investment. Please check the relationship between BridgeBio Pharma Cash and its Net Debt accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BridgeBio Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

To learn how to invest in BridgeBio Stock, please use our How to Invest in BridgeBio Pharma guide.

Cash vs Net Debt

Cash vs Net Debt Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of BridgeBio Pharma Cash account and Net Debt. At this time, the significance of the direction appears to have no relationship.

The correlation between BridgeBio Pharma's Cash and Net Debt is 0.08. Overlapping area represents the amount of variation of Cash that can explain the historical movement of Net Debt in the same time period over historical financial statements of BridgeBio Pharma, assuming nothing else is changed. The correlation between historical values of BridgeBio Pharma's Cash and Net Debt is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Cash of BridgeBio Pharma are associated (or correlated) with its Net Debt. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Debt has no effect on the direction of Cash i.e., BridgeBio Pharma's Cash and Net Debt go up and down completely randomly.

Correlation Coefficient

0.08

Relationship Direction	Positive
Relationship Strength	Insignificant

View All Relationships

Cash

Cash refers to the most liquid asset of BridgeBio Pharma, which is listed under current asset account on BridgeBio Pharma balance sheet and usually includes currency, coins, checking accounts, and not deposited checks received from BridgeBio Pharma customers. The amounts must be unrestricted with restricted cash listed in a different BridgeBio Pharma account. The total amount of money in the form of currency that a company has in its possession. This includes all bills, coins, and funds in bank accounts.

Net Debt

The total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds.

Most indicators from BridgeBio Pharma's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into BridgeBio Pharma current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BridgeBio Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

To learn how to invest in BridgeBio Stock, please use our How to Invest in BridgeBio Pharma guide.As of the 23rd of March 2025, Tax Provision is likely to grow to about 1.2 M, while Selling General Administrative is likely to drop about 147.4 M.

	2022	2023	2024	2025 (projected)
Reconciled Depreciation	6.8M	6.5M	6.1M	4.5M
Total Operating Expenses	546.1M	614.2M	811.0M	499.4M

Reconciled Depreciation Total Operating Expenses

BridgeBio Pharma fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Property Plant And Equipment Gross	Total Current Assets	Non Current Liabilities Other	Net Working Capital
Total Assets		0.85	0.91	-0.62	0.74	-0.57	0.82	0.29	-0.77	0.88	0.92	0.87	0.8	0.66	0.99	-0.74	0.82	0.81	0.78	0.8	0.82	0.88	0.82	0.99	0.64	0.98
Other Current Liab	0.85		0.98	-0.86	0.9	-0.86	0.82	0.52	-0.9	0.74	0.79	0.85	0.95	0.81	0.79	-0.75	0.95	0.95	0.81	0.79	0.96	0.76	0.82	0.81	0.64	0.76
Total Current Liabilities	0.91	0.98		-0.83	0.9	-0.82	0.79	0.46	-0.92	0.81	0.87	0.87	0.89	0.84	0.86	-0.8	0.97	0.95	0.83	0.86	0.95	0.81	0.79	0.88	0.59	0.83
Total Stockholder Equity	-0.62	-0.86	-0.83		-0.96	0.97	-0.52	-0.36	0.93	-0.6	-0.67	-0.84	-0.75	-0.92	-0.53	0.56	-0.9	-0.93	-0.55	-0.73	-0.93	-0.46	-0.52	-0.56	-0.31	-0.5
Other Liab	0.74	0.9	0.9	-0.96		-0.96	0.64	0.36	-0.97	0.64	0.72	0.92	0.8	0.95	0.66	-0.75	0.95	0.93	0.68	0.85	0.93	0.64	0.64	0.69	0.4	0.62
Net Tangible Assets	-0.57	-0.86	-0.82	0.97	-0.96		-0.57	-0.5	0.89	-0.5	-0.55	-0.8	-0.78	-0.88	-0.47	0.65	-0.89	-0.91	-0.58	-0.68	-0.9	-0.52	-0.57	-0.51	-0.41	-0.43
Property Plant And Equipment Net	0.82	0.82	0.79	-0.52	0.64	-0.57		0.6	-0.6	0.69	0.58	0.71	0.93	0.47	0.8	-0.74	0.66	0.68	0.84	0.58	0.69	0.91	1.0	0.82	0.9	0.81
Net Debt	0.29	0.52	0.46	-0.36	0.36	-0.5	0.6		-0.23	0.34	0.08	0.17	0.63	0.21	0.24	-0.4	0.36	0.47	0.45	0.05	0.47	0.54	0.6	0.28	0.77	0.23
Retained Earnings	-0.77	-0.9	-0.92	0.93	-0.97	0.89	-0.6	-0.23		-0.69	-0.81	-0.9	-0.76	-0.97	-0.71	0.75	-0.96	-0.91	-0.71	-0.93	-0.91	-0.62	-0.6	-0.73	-0.31	-0.67
Accounts Payable	0.88	0.74	0.81	-0.6	0.64	-0.5	0.69	0.34	-0.69		0.89	0.71	0.68	0.63	0.89	-0.49	0.69	0.74	0.7	0.67	0.74	0.72	0.69	0.9	0.55	0.89
Cash	0.92	0.79	0.87	-0.67	0.72	-0.55	0.58	0.08	-0.81	0.89		0.82	0.64	0.74	0.91	-0.57	0.83	0.81	0.68	0.83	0.82	0.64	0.58	0.91	0.35	0.89
Non Current Assets Total	0.87	0.85	0.87	-0.84	0.92	-0.8	0.71	0.17	-0.9	0.71	0.82		0.79	0.83	0.82	-0.72	0.88	0.87	0.66	0.85	0.87	0.72	0.71	0.83	0.46	0.8
Non Currrent Assets Other	0.8	0.95	0.89	-0.75	0.8	-0.78	0.93	0.63	-0.76	0.68	0.64	0.79		0.64	0.75	-0.71	0.82	0.86	0.8	0.65	0.86	0.8	0.93	0.77	0.8	0.73
Other Assets	0.66	0.81	0.84	-0.92	0.95	-0.88	0.47	0.21	-0.97	0.63	0.74	0.83	0.64		0.59	-0.7	0.91	0.85	0.67	0.88	0.85	0.52	0.47	0.62	0.2	0.55
Cash And Short Term Investments	0.99	0.79	0.86	-0.53	0.66	-0.47	0.8	0.24	-0.71	0.89	0.91	0.82	0.75	0.59		-0.7	0.76	0.73	0.76	0.78	0.75	0.87	0.8	1.0	0.61	1.0
Common Stock Total Equity	-0.74	-0.75	-0.8	0.56	-0.75	0.65	-0.74	-0.4	0.75	-0.49	-0.57	-0.72	-0.71	-0.7	-0.7		-0.78	-0.65	-0.82	-0.82	-0.67	-0.87	-0.74	-0.72	-0.56	-0.67
Common Stock Shares Outstanding	0.82	0.95	0.97	-0.9	0.95	-0.89	0.66	0.36	-0.96	0.69	0.83	0.88	0.82	0.91	0.76	-0.78		0.96	0.73	0.87	0.97	0.68	0.66	0.78	0.43	0.71
Non Current Liabilities Total	0.81	0.95	0.95	-0.93	0.93	-0.91	0.68	0.47	-0.91	0.74	0.81	0.87	0.86	0.85	0.73	-0.65	0.96		0.67	0.74	1.0	0.65	0.68	0.76	0.52	0.7
Other Current Assets	0.78	0.81	0.83	-0.55	0.68	-0.58	0.84	0.45	-0.71	0.7	0.68	0.66	0.8	0.67	0.76	-0.82	0.73	0.67		0.75	0.69	0.82	0.84	0.78	0.69	0.74
Other Stockholder Equity	0.8	0.79	0.86	-0.73	0.85	-0.68	0.58	0.05	-0.93	0.67	0.83	0.85	0.65	0.88	0.78	-0.82	0.87	0.74	0.75		0.75	0.68	0.58	0.79	0.24	0.74
Total Liab	0.82	0.96	0.95	-0.93	0.93	-0.9	0.69	0.47	-0.91	0.74	0.82	0.87	0.86	0.85	0.75	-0.67	0.97	1.0	0.69	0.75		0.66	0.69	0.77	0.53	0.71
Net Invested Capital	0.88	0.76	0.81	-0.46	0.64	-0.52	0.91	0.54	-0.62	0.72	0.64	0.72	0.8	0.52	0.87	-0.87	0.68	0.65	0.82	0.68	0.66		0.91	0.89	0.81	0.87
Property Plant And Equipment Gross	0.82	0.82	0.79	-0.52	0.64	-0.57	1.0	0.6	-0.6	0.69	0.58	0.71	0.93	0.47	0.8	-0.74	0.66	0.68	0.84	0.58	0.69	0.91		0.82	0.9	0.81
Total Current Assets	0.99	0.81	0.88	-0.56	0.69	-0.51	0.82	0.28	-0.73	0.9	0.91	0.83	0.77	0.62	1.0	-0.72	0.78	0.76	0.78	0.79	0.77	0.89	0.82		0.63	0.99
Non Current Liabilities Other	0.64	0.64	0.59	-0.31	0.4	-0.41	0.9	0.77	-0.31	0.55	0.35	0.46	0.8	0.2	0.61	-0.56	0.43	0.52	0.69	0.24	0.53	0.81	0.9	0.63		0.63
Net Working Capital	0.98	0.76	0.83	-0.5	0.62	-0.43	0.81	0.23	-0.67	0.89	0.89	0.8	0.73	0.55	1.0	-0.67	0.71	0.7	0.74	0.74	0.71	0.87	0.81	0.99	0.63

Click cells to compare fundamentals

BridgeBio Pharma Account Relationship Matchups

BridgeBio Pharma fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	703.6M	1.0B	623.0M	546.4M	919.3M	687.5M
Other Current Liab	81.5M	118.2M	98.0M	123.0M	125.7M	79.2M
Total Current Liabilities	91.9M	130.1M	117.8M	143.8M	154.4M	100.6M
Total Stockholder Equity	57.9M	(870.4M)	(1.3B)	(1.4B)	(1.5B)	(1.4B)
Other Liab	3.5M	7.9M	22.1M	26.6M	30.6M	32.2M
Net Tangible Assets	408.5M	59.5M	(915.3M)	(1.3B)	(1.2B)	(1.1B)
Property Plant And Equipment Net	36.8M	46.0M	25.2M	19.8M	12.8M	20.4M
Net Debt	139.7M	1.3B	1.3B	1.4B	(671.9M)	(638.3M)
Retained Earnings	(888.8M)	(1.4B)	(1.9B)	(2.6B)	(3.1B)	(2.9B)
Accounts Payable	8.9M	11.9M	11.6M	10.7M	9.6M	10.6M
Cash	356.1M	393.8M	376.7M	375.9M	681.1M	422.9M
Non Current Assets Total	60.8M	173.1M	117.8M	68.8M	198.6M	208.6M
Non Currrent Assets Other	21.3M	33.0M	20.2M	22.6M	18.2M	15.4M
Other Assets	26.3M	23.9M	33.0M	140.8M	161.9M	170.0M
Cash And Short Term Investments	607.1M	787.5M	428.3M	434.9M	681.1M	556.1M
Common Stock Total Equity	124K	125K	154K	157K	141.3K	134.2K
Common Stock Shares Outstanding	118.0M	144.4M	147.5M	162.8M	186.1M	144.2M
Liabilities And Stockholders Equity	703.6M	1.0B	623.0M	546.4M	919.3M	687.5M
Non Current Liabilities Total	503.8M	1.7B	1.8B	1.7B	2.2B	1.2B
Other Current Assets	71.3M	32.4M	59.9M	41.0M	34.9M	36.4M
Other Stockholder Equity	946.3M	566.5M	663.7M	1.2B	1.6B	1.7B
Total Liab	595.7M	1.9B	1.9B	1.9B	2.4B	1.3B
Net Invested Capital	535.2M	833.4M	453.0M	372.5M	253.5M	382.3M
Property Plant And Equipment Gross	36.8M	46.0M	25.2M	19.8M	12.8M	20.4M
Total Current Assets	642.8M	839.7M	505.2M	477.6M	720.7M	595.1M
Accumulated Other Comprehensive Income	192K	(132K)	(328K)	31K	8K	8.4K
Non Current Liabilities Other	24.2M	39.5M	26.6M	9.4M	286K	271.7K
Net Working Capital	547.2M	709.6M	387.4M	333.7M	566.3M	488.6M
Common Stock	125K	154K	157K	181K	196K	186.2K
Property Plant Equipment	5.6M	20.3M	46.0M	14.6M	16.8M	16.2M
Short Long Term Debt Total	495.8M	1.7B	1.7B	1.7B	9.2M	8.7M
Long Term Debt	475.9M	1.7B	1.7B	1.7B	1.7B	1.2B
Long Term Debt Total	91.8M	475.9M	1.7B	1.7B	2.0B	2.1B
Capital Stock	125K	154K	157K	181K	196K	186.2K
Capital Lease Obligations	18.5M	22.4M	15.9M	13.1M	9.2M	11.6M

When determining whether BridgeBio Pharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of BridgeBio Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bridgebio Pharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bridgebio Pharma Stock:

How To Invest In BridgeBio

Details

Is BridgeBio Stock a good investment?

Details

What is BridgeBio Pharma's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BridgeBio Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

To learn how to invest in BridgeBio Stock, please use our How to Invest in BridgeBio Pharma guide.

You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BridgeBio Pharma. If investors know BridgeBio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BridgeBio Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(2.88)

Revenue Per Share

1.193

Quarterly Revenue Growth

2.371

Return On Assets

(0.48)

Return On Equity

(17.90)

The market value of BridgeBio Pharma is measured differently than its book value, which is the value of BridgeBio that is recorded on the company's balance sheet. Investors also form their own opinion of BridgeBio Pharma's value that differs from its market value or its book value, called intrinsic value, which is BridgeBio Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BridgeBio Pharma's market value can be influenced by many factors that don't directly affect BridgeBio Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between BridgeBio Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if BridgeBio Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BridgeBio Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

BridgeBio Cash vs Net Debt Analysis

Cash vs Net Debt

Cash vs Net Debt Correlation Analysis

Correlation Coefficient

Cash

Net Debt

BridgeBio Pharma fundamental ratios Correlations

BridgeBio Pharma Account Relationship Matchups

High Positive Relationship

High Negative Relationship

BridgeBio Pharma fundamental ratios Accounts

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Property Plant And Equipment Gross	+ 1.0	Property Plant And Equipment Net
Total Current Assets	+ 1.0	Cash And Short Term Investments
Net Working Capital	+ 1.0	Cash And Short Term Investments
Total Liab	+ 1.0	Non Current Liabilities Total
Cash And Short Term Investments	+ 0.99	Total Assets
Total Current Assets	+ 0.99	Total Assets

Other Assets	- 0.97	Retained Earnings
Retained Earnings	- 0.97	Other Liab
Common Stock Shares Outstanding	- 0.96	Retained Earnings
Net Tangible Assets	- 0.96	Other Liab
Other Liab	- 0.96	Total Stockholder Equity
Other Stockholder Equity	- 0.93	Retained Earnings